Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isodeoxyelephantopin is a natural sesquiterpene lactone isolated primarily from Elephantopus scaber and Elephantopus carolinianus, plants used in traditional Asian medicine. It displays anti-cancer and anti-inflammatory effects by targeting multiple intracellular signaling pathways. Its anti-tumor activity involves the induction of apoptosis, cell cycle arrest (notably G2/M), and autophagy in cancer cells through modulation of pathways such as NF-κB, AP-1, and MAPK, and generation of reactive oxygen species (ROS). Isodeoxyelephantopin also inhibits inflammatory mediators (including inducible nitric oxide synthase, interleukins, and chemokines) in macrophages by suppressing nuclear factor-κB and activator protein-1 activity. The compound is under early preclinical investigation for its use against breast, lung, leukemia, and other cancer types, as well as inflammatory conditions[1][3][5][6][7][9][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isodeoxyelephantopin.